InsidersTradesSigma
申报总数
公司
▲ 买入（3 笔）
▼ 卖出（0 笔）
内部人交易记录
首席财务官已披露买入
3
已披露卖出
0
尚无足够的、已确定 T+90 期限的买入信号来衡量交易记录。
信号历史
Discover the detailed record of transactions filed by Levine James E., 首席财务官. Director active across 1 company, notably Cardiff Oncology, Inc.. In total, 3 reports have been logged. Split: 3 buys · 0 sell. Total volume traded: €84k. Activity tracked since 10 September 2021. The latest transaction was filed on 16 December 2024 (Acquisition). Regulator: SEC (Form 4). The full history is free.
Companies and markets linked to Levine James E.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报3 总计
2,564 股@ US$3.838.3% 占其流量Common StockSEC:0000950170-24-137938:0
标准退出：2025年3月16日 (T+90)
30,000 股@ US$1.55741.7% 占其流量Common StockSEC:0001628280-22-025099:0
标准退出：2022年12月15日 (T+90)
5,000 股@ US$6.6233.3% 占其流量Common StockSEC:0001628280-21-018433:0
标准退出：2021年12月9日 (T+90)
3 条申报中的 3 条
About Levine James E.
James E. Levine is the Chief Financial Officer at Cardiff Oncology, Inc. He is responsible for the financial management of the company, including financial planning and analysis. With a strong background in the healthcare sector, he contributes to Cardiff's mission of developing innovative treatments for patients.
